Xylem Inc’s recent filing unveils that its Officer DOROTHY CAPERS acquired Company’s shares for reported $1.53 million on Mar 04 ’25. In the deal valued at $127.26 per share,12,026 shares were bought.
Then, Cerwinka Franz bought 9,513 shares, generating $1,214,714 in total proceeds.
Before that, FRANZ CERWINKA bought 8,500 shares. Xylem Inc shares valued at $1,085,112 were divested by the Officer at a price of $127.66 per share.
Wolfe Research downgraded its Xylem Inc [XYL] rating to a Peer perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who increased its forecast for the stock in early December from “a Neutral” to “a Buy”. TD Cowen also remained covering XYL and has decreased its forecast on September 03, 2024 with a “Hold” recommendation from previously “Buy” rating. UBS started covering the stock on August 13, 2024. It rated XYL as “a Buy”.
Price Performance Review of XYL
On Tuesday, Xylem Inc [NYSE:XYL] saw its stock fall -1.90% to $127.32. Over the last five days, the stock has lost -0.58%. Xylem Inc shares have risen nearly 9.74% since the year began. Nevertheless, the stocks have risen 0.21% over the past one year. While a 52-week high of $146.08 was reached on 02/11/25, a 52-week low of $113.26 was recorded on 01/13/25. SMA at 50 days reached $123.01, while 200 days put it at $130.46.
Levels Of Support And Resistance For XYL Stock
The 24-hour chart illustrates a support level at 126.14, which if violated will result in even more drops to 124.97. On the upside, there is a resistance level at 128.87. A further resistance level may holdings at 130.43. The Relative Strength Index (RSI) on the 14-day chart is 49.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.15%. Stochastics %K at 46.65% indicates the stock is a holding.
The most recent change occurred on March 12, 2024 when Exane BNP Paribas began covering the stock and recommended ‘”an Outperform”‘ rating along with a $150 price target.
